Histone deacetylase (HDAC) inhibitors were tested in experimental diabetes with some favorable effect: vorinostat, a nonspecific HDAC inhibitor, showed beneficial effects on diabetic nephropathy in mice [82]. Here, HDAC9 is linked to diabetic kidney disease.